Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PMV PHARMACEUTICALS, INC.

(PMVP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
25.12(c) 24.54(c) 24.84(c) 23.97(c) 23.15(c) Last
419 531 306 148 336 933 401 481 245 686 Volume
+2.99% -2.31% +1.22% -3.50% -3.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -55,6 M - -
Net cash position 2021 168 M - -
P/E ratio 2021 -18,7x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -82,5 M - -
Net cash position 2022 113 M - -
P/E ratio 2022 -12,8x
Yield 2022 -
Capitalization 1 051 M 1 051 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 44
Free-Float 88,1%
More Financials
Company
PMV Pharmaceuticals, Inc. is a precision oncology company. PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations. ItÔÇÖs lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. The... 
More about the company
Ratings of PMV Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about PMV PHARMACEUTICALS, INC.
11/22PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
GL
11/12PMV Pharmaceuticals Logs Narrower Q3 Loss Amid Higher Spending
MT
11/12PMV PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/12PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highligh..
PU
11/12PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/12PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highligh..
AQ
10/05PMV PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
AQ
10/05PMV PHARMACEUTICALS : Files for Mixed-Securities Shelf
MT
09/29INSIDER SELL : Pmv Pharmaceuticals
MT
09/28NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/23JOHN CHEN : Stock Futures -3-
DJ
09/22PMV PHARMACEUTICALS : Goldman Sachs Upgrades PMV Pharmaceuticals to Buy From Neutral, Lift..
MT
09/14INSIDER SELL : Pmv Pharmaceuticals
MT
09/09PMV PHARMACEUTICALS : Appoints Tim Smith as Senior Vice President, Head of Corporate Devel..
AQ
09/09PMV Pharmaceuticals, Inc. Appoints Tim Smith as Senior Vice President, Head of Corporat..
CI
More news
News in other languages on PMV PHARMACEUTICALS, INC.
11/12PMV Pharmaceuticals enregistre une perte plus importante au troisième trimestre en rais..
10/05PMV Pharmaceuticals dépose une demande d'inscription au rayon des titres mixtes
More news
Analyst Recommendations on PMV PHARMACEUTICALS, INC.
More recommendations
Chart PMV PHARMACEUTICALS, INC.
Duration : Period :
PMV Pharmaceuticals, Inc. Technical Analysis Chart | PMVP | US69353Y1038 | MarketScreener
Technical analysis trends PMV PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 23,15 $
Average target price 62,20 $
Spread / Average Target 169%
EPS Revisions
Managers and Directors
David H. Mack President, Chief Executive Officer & Director
Winston Kung Chief Operating & Financial Officer
Richard A. Heyman Chairman
Leila Alland Chief Medical Officer
Arnold Jay Levine Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PMV PHARMACEUTICALS, INC.-62.36%1 051
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678